


The Total Synthesis of Scytophycin C. Part 2: Synthesis of Scytophycin C from the Protected Seco Acid.

Ian Paterson,* Christine Watson, Kap-Sun Yeung,
Richard A. Ward and Paul A. Wallace

University Chemical Laboratory, Lensfield Road, Cambridge CB2 1EW, UK.

Received 15 May 1998; revised 17 July 1998; accepted 22 July 1998

Abstract: Scytophycin C (**1**) was synthesised in 8 steps from the fully protected seco acid **2**. Key steps include: (i) a high yielding macrolactonisation reaction of **15** followed by regioselective isomerisation of the undesired, 24-membered macrolide, **18** → **16**; (ii) the chemoselective oxidation steps, **16** → **6** and **7** → **8**; (iii) the P₂O₅-promoted condensation of **8** with HN(Me)CHO to install the *N*-methyl vinylformamide moiety in **1**. © 1998 Elsevier Science Ltd. All rights reserved.




Scheme 1

In the preceding paper, we outlined our strategy for the total synthesis of the 22-membered macrolide, scytophycin C (**1**).¹ Following this strategy, a stereocontrolled synthesis of the advanced intermediate **2**

(**Scheme 1**), representing a fully protected seco acid incorporating all 15 stereogenic centres, was achieved in a direct and efficient manner. In this paper, we give full details of the further elaboration of **2** and completion of the first total synthesis of scytophycin C (**1**).² Notably, the crucial ring-closure step and final functional group adjustments proved much more challenging than that encountered in the late stages of our synthesis³ of the related macrolides, swinholide A (**3**) and hemiswinholide A (**4**).

Strategy for Completing the Total Synthesis of Scytophycin C




Scheme 2

Our initial plans for completing the total synthesis of scytophycin C (**1**) are summarised in **Scheme 2**. Ideally, the C₂₇ ketone functionality of scytophycin C might be taken through the remainder of the synthesis without the need for further protecting group chemistry. We initially anticipated that such a substrate could be prepared by cleavage of the C₁ methyl ester and deprotection of the di-*tert*-butylsilylene group to release a 1,3-diol, as in **2** → **5**. Use of this cyclic silicon protecting group precluded selective deprotection of the C₂₁ hydroxyl group and thus necessitated a regioselective macrolactonisation step. While the two secondary alcohols in **5** appear to have similar steric environments, by using the Yamaguchi macrolactonisation method⁴ some selectivity for acylation at the C₂₁ over the C₂₃ hydroxyl, leading to the desired 22-membered macrolide **6**, was anticipated based on our total synthesis of hemiswinholide A (**4**).³

Following deprotection of **6** to give **7**, the macrolactone **8** might then be accessed by selective oxidation of the primary C₃₂ alcohol in the presence of the two secondary alcohols at C₇ and C₂₃. The final step, *i.e.*

introduction of the *N*-methyl vinylformamide group, as in **8** → **1**, was anticipated to be particularly challenging as a result of the known acid sensitivity of the scytophycins.⁵ However, it was hoped that mild, acid-catalysed, condensation of *N*-methyl formamide onto the aldehyde group in **8** would enable the completion of the total synthesis of scytophycin C (**1**).

Macrolactonisation Studies Leading to the Synthesis of Macrolide (**16**)




Scheme 3: (a) Ba(OH)₂, MeOH, 20 °C, 8 h; (b) NaBH₄, MeOH, -20 °C, 18 h; (c) TMSOK, Et₂O, 20 °C, 48 h; (d) Dess-Martin periodinane, CH₂Cl₂, 20 °C, 2 h; (e) HF·py, py, THF, 0 °C, 90 min.

Following this strategy, an investigation of the macrolactonisation reaction first required controlled hydrolysis of the methyl ester in **2** to generate the corresponding carboxylic acid (**Scheme 3**). Unfortunately, we were unable to achieve this apparently simple transformation without complications from the presence of the unprotected C₂₇ ketone. Under standard basic conditions (Ba(OH)₂, MeOH), the enone **9** was obtained exclusively, resulting from elimination of MeOH across C₂₈ and C₂₉ (the product alkene stereochemistry was not determined). Screening of a wide range of basic and nucleophilic conditions (*e.g.* LiOH; LiOOH; LiI/pyridine;⁶ TMSOK⁷) resulted in this same undesired carboxylic acid being isolated.

To overcome this problem, the C₂₇ ketone was temporarily “protected” as the corresponding secondary alcohol during the ester hydrolysis reaction. Thus, the fully protected seco acid **2** was reduced with NaBH₄ (MeOH, –20 °C) to give the alcohol **10** as a single diastereomer in 77% yield (99% based on recovered starting material). The resulting stereochemistry at C₂₇ was not determined and is assigned as shown based on the operation of Felkin-Anh selectivity. With the base-sensitive ketone group now removed, hydrolysis of the methyl ester proceeded cleanly using potassium trimethylsilanoate⁷ (Et₂O, 20 °C). Reoxidation at C₂₇ using the Dess-Martin periodinane⁸ then generated the desired ketoacid **11** in 86% overall yield.


We now required selective deprotection of the silylene group in **11** in the presence of the TIPS and TBS groups to generate the required macrolactonisation substrate **5** (cf. Scheme 2). This was achieved smoothly using HF•pyridine (pyridine, THF).⁹ However, the deprotected product was not isolated as the diol acid **5** but as the corresponding hemiacetal **12**, where the C₂₃ hydroxyl had closed onto the ketone at C₂₇. Further cyclisation involving the free C₂₁ hydroxyl to generate a bicyclic acetal from **12** was not observed. Notably, this tautomeric hemiacetal does not appear to form in the scytophycins, presumably due to the steric demands of the macrolide ring. For synthetic purposes, the alcohol at C₂₃ had effectively been protected by forming the hemiacetal **12** and would presumably be unable to participate in the macrolactonisation reaction to generate the undesired, 24-membered macrolide. Thus, a completely regiocontrolled macrolactonisation appeared possible by selective acylation of the C₂₁ hydroxyl group.



Scheme 4

Following the successful macrolactonisation protocol adopted earlier for the formation of the 22-membered ring in hemiswinholide A (**4**),³ the seco acid **12** was subjected to cyclisation under Yamaguchi conditions⁴ in toluene (2,4,6-Cl₃(C₆H₂)COCl, Et₃N; 4-DMAP, 60 °C). Even under forcing conditions (further heating, large excess of reagent), no reaction was observed and the seco acid **12** was recovered in varying yield. In comparison, the corresponding macrolactonisation of seco acid **13**, cf. Scheme 4, proceeded without difficulty in excellent yield (92%) and a high level of regioselectivity (82 : 18) towards the 22-membered ring **14**, as required for hemiswinholide A (**4**), was achieved. To our dismay, formation of the hemiacetal in **12** apparently increased the steric hindrance around the C₂₁ hydroxyl so much that it precluded intramolecular acylation. In the light of these disappointing results, we required a new strategy which would enable us to overcome the ketone-related problems of β-elimination and hemiacetal formation.

One bold approach for advancing the synthesis further is shown in **Scheme 5**. As the reduction of the C₂₇ ketone was dictated by the need to achieve trouble-free ester hydrolysis, we now proposed to postpone the re-oxidation at C₂₇ until after the key macrolactonisation reaction. In this way, hemiacetal formation would be prevented with no increase in the number of synthetic steps. The disadvantages of such an approach were obvious. Firstly, the macrolactonisation reaction would now be even more challenging with *three free hydroxyl groups available for acylation* in the new substrate **15**, leading potentially to 22-, 24- and 28-membered rings. Secondly, reoxidation at C₂₇, as in **16** → **6**, might no longer be straightforward. Nevertheless, chemoselectivity over competing C₂₃ oxidation might still be possible as a result of the different steric environments of the two secondary alcohols in **16**. Final completion of the synthesis of scytophycin C from **6** was envisaged to proceed as proposed in **Scheme 2**.




Scheme 5

The first two steps of this new route proved to be straightforward (**Scheme 6**). The triol acid **15** was prepared from **10** in 91% yield by silylene deprotection (HF•py, pyridine, THF) to give the triol **17** followed by ester hydrolysis (Ba(OH)₂, MeOH). The key macrolactonisation step was now investigated. Initially, we decided to employ modified Yamaguchi conditions as these had given remarkable selectivity in favour of the desired 22-membered over the isomeric 24-membered ring in our synthesis of hemiswinholide A (**4**), *cf.* **Scheme 4**. Treatment of the acid **15** under Yonemitsu's conditions,¹⁰ using 2,4,6-trichlorobenzoyl chloride, Et₃N and 4-DMAP in toluene (20 °C, 8 h), resulted in an excellent yield (90%) of a 42 : 58 mixture of two macrocycles, **16** and **18**. Unfortunately, this mixture was slightly in favour of the 24-membered over the desired 22-membered ring. No acylation at C₂₇ to form the 28-membered macrolide **19** was detected. Reaction in a more polar solvent (CH₂Cl₂) reversed this selectivity to now favour **16** (along with a small amount of an isomeric macrolide which was tentatively assigned as **19**); however, the yield (54%) was substantially lower. Other macrolactonisation procedures investigated (Keck,¹¹ Mukaiyama¹²) gave rise to poor selectivities and low yields. We were unable to attain the level of macrolactonisation regioselectivity achieved in the equivalent hemiswinholide reaction, *i.e.* **13** → **14** in **Scheme 4**, which benefits from the presence of a cyclic acetal protecting group across the equivalent C₁₇ and C₁₉ hydroxyls acting as an additional conformational anchor.

Under kinetic macrolactonisation conditions using the Yonemitsu procedure (without recourse to high dilution techniques), a high yield of the separable macrolactones **16** and **18** could be obtained. Presumably, the conformational preferences of the molecular backbone makes the participation of the hydroxyl at C₂₇ in the


intramolecular esterification step less favoured than those at C₂₁ and C₂₃. However, a method for recycling the 24-membered ring **18** was required to obtain sufficient stocks of **16** to complete the synthesis of scytophycin C. Titanium tetrakisopropoxide is a mild reagent known to mediate transesterification reactions on complex, highly functionalised compounds.^{13,14} Thus the undesired macrocycle **18** was treated with a 1M solution of Ti(OⁱPr)₄ in CH₂Cl₂ (**Scheme 6**). After 48 h at ambient temperature, a 70 : 30 mixture of **16** and **18** was isolated in 91% yield. Thus under equilibrating conditions, the 24-membered ring **18** could be isomerised to the desired 22-membered ring **16** with excellent mass recovery. In contrast, attempts to carry out the macrolactonisation reaction directly on the methyl ester **17**, under thermodynamic conditions ([Bu₂SnCl(OH)₂]₂[Bu₂SnO]₂, PhMe),¹⁵ failed to give any detectable macrolide products.



Scheme 6: (a) HF·py, py, THF, 0 → 20 °C, 1 h; (b) Ba(OH)₂, MeOH, 20 °C, 18 h; (c) 2,4,6-(C₆H₂)COCl, Et₃N, 4-DMAP, PhMe, 20 °C, 18 h; (d) 2,4,6-(C₆H₂)COCl, Et₃N, 4-DMAP, CH₂Cl₂, 20 °C, 18 h; (e) DCC, 4-DMAP, 4-DMAP·HCl, PhMe, 60 °C, 16 h; (f) 2-chloro-*N*-methylpyridinium iodide, Et₃N, MeCN, 80 °C, 18 h; (g) Ti(OⁱPr)₄, CH₂Cl₂, 20 °C, 48 h.

Completing the Total Synthesis of Scytophycin C (1)

While the free hydroxyl group at C₂₇ did not participate in the macrolactonisation reaction, selective re-oxidation at this position over the C₂₃ alcohol remained as a potential problem. As shown in **Scheme 7**, tetrapropylammonium perruthenate (TPAP)¹⁶ was selected as a sterically demanding oxidant, where the proximity of the C₂₃ hydroxyl to the macrolide ring was anticipated to interfere with the oxidation reaction at this position. In the event, treatment of **16** with 0.2 equivalents of TPAP (NMO, CH₂Cl₂, molecular sieves) for 1 h at room temperature gave the desired ketone **6** in 80% yield with no oxidation at C₂₃ observed.



Scheme 7: (a) TPAP, NMO, CH₂Cl₂, 4Å mol sieves, 20 °C, 1 h; (b) HF·py, py, THF, 20 °C, 48 h; (c) TPAP, NMO, CH₂Cl₂, 4Å mol sieves, 0 °C, 30 min; (d) aq. HF, MeCN, 20 °C, 20 min; (e) TPAP, NMO, CH₂Cl₂, 4Å mol sieves, 20 °C, 2 h.

At this stage, we hoped to minimise further protecting group manipulations by carrying out a global deprotection. Treatment of **6** with HF·py (pyridine, THF) for 48 h resulted in a mixture of the desired triol **7** (64%) and monodeprotected intermediates (36%) which could be readily recycled. Attempts to improve the yield and rate of this reaction using HF or TBAF resulted in a complex mixture of products in both cases, including some eliminated material. We now required a further selective oxidation, this time of a primary alcohol in the presence of the secondary hydroxyl groups at C₇ and C₂₃. As TPAP had proved to be a mild and selective reagent in the oxidation of **16**, it was the obvious choice for this second oxidation. Thus triol **7** was treated with TPAP and NMO, in the presence of powdered molecular sieves, for 30 min at 0 °C. On work-up,

The entire synthesis of scytophycin C proceeds in a total of 41 steps (22 steps longest linear sequence) with an overall yield of 0.7%. The stereocontrolled construction of the protected seco acid **2** relied heavily on various types of asymmetric aldol reactions, which were used to form the C₆–C₇, C₁₂–C₁₃, C₁₈–C₁₉ and C₂₂–C₂₃ bonds. Notably, the regioselectivity of macrolactonisation was controlled without the need for differential hydroxyl protection by taking advantage of the thermodynamic preference for the smaller, 22-membered ring, **16**. The final step of the synthesis, *i.e.* **8** → **1**, proved to be especially challenging due to the acid-sensitivity of this system and improved methods are clearly needed for the introduction of such *N*-methyl vinylformamide units, as they occur in a variety of marine macrolide structures. With further work, this route should allow the preparation of a range of structural analogues of the scytophycins, enabling the mode of action and structure-activity relationships to be probed.

Experimental Section

For general experimental details, see the preceding paper.

C₂₇ Alcohol (10) To a cooled (–20 °C), stirred solution of ketone **2** (190 mg, 0.160 mmol) in MeOH (10 ml) was added NaBH₄ (183 mg, 4.82 mmol) in one portion. The reaction mixture was warmed gradually, over 3 h, to 0 °C then stirred at this temperature for 1 h. The reaction was quenched with NaHCO₃ (10 ml, sat. aq.) and diluted with Et₂O (20 ml). The layers were separated and the aqueous layer was extracted with Et₂O (3 x 25 ml). The combined organic extracts were dried (MgSO₄) and concentrated *in vacuo*. Flash column chromatography (30 → 50% Et₂O/hexane) gave some recovered **2** (43 mg, 23%) and product **10** as a colourless oil (146 mg, 77%); R_f 0.33 (40% Et₂O/hexane); [α]_D²⁰ –46.8 (*c* 1.4, CHCl₃); IR (liquid film) 2937, 2863, 1722, 1623, 1463, 1387, 1256, 1091, 983 cm⁻¹; ¹H NMR δ (CDCl₃, 500 MHz) 7.33 (1H, d, *J* = 15.7 Hz, 3-CH), 6.04 (1H, t, *J* = 6.8 Hz, 5-CH), 5.80–5.77 (2H, br d, *J* = 15.7 Hz, 2-CH, 11-CH), 5.64 (1H, d, *J* = 10.1 Hz, 10-CH) 4.33 (1H, d, *J* = 10.1 Hz, 9-CH), 4.20–4.10 (1H, m, 7-CH), 4.16 (1H, br d, *J* = 11.6 Hz, 21-CH), 4.05 (1H, d, *J* = 7.6 Hz, CHO), 3.79–3.75 (1H, m, 32-CH_ACH_B), 3.75 (3H, s, CO₂Me), 3.70–3.63 (3H, m, 32-CH_ACH_B, 23-CH, CHO), 3.60–3.53 (2H, m, 13-CH, CHO), 3.48 (3H, s, OMe), 3.44 (3H, s, OMe), 3.34 (3H, s, OMe), 3.30 (3H, s, OMe), 3.07 (1H, t, *J* = 7.9 Hz, CHO), 2.97 (1H, dd, *J* = 8.3, 2.4 Hz, CHO), 2.47–2.42 (1H, m, 6-CH_ACH_B), 2.42–2.35 (1H, m, 6-CH_ACH_B), 2.02–1.85 (3H, m, 3xCH), 2.02–1.95 (1H, m, 12-CH_ACH_B), 1.95–1.85 (1H, m, 12-CH_ACH_B), 1.75 (3H, s, 4-CMe), 1.76–1.70 (7H, m, 31-CH_ACH_B, 22-CH, 20-CH, 4xCH), 1.65–1.58 (3H, m, 8-CH_ACH_B, 2xCH), 1.43–1.40 (1H, m, 8-CH_ACH_B), 1.50–1.40 (2H, hidden m, 2xCH), 1.35–1.28 (2H, m, 31-CH_ACH_B, CH), 1.06 (18H, br s, (Me₂CH)₃Si), 1.05 (9H, s, ^tBu), 1.02 (9H, s, ^tBu), 1.04–1.02 (3H, hidden d, CHMe), 1.10–0.98 (3H, m, (Me₂CH)₃Si), 0.91 (3H, d, *J* = 7.2 Hz, CHMe), 0.89 (12H, s+hidden d, SiMe₂^tBu, CHMe), 0.86 (3H, d, *J* = 7.2 Hz, CHMe), 0.83 (3H, d, *J* = 7.2 Hz, CHMe), 0.74 (3H, d, *J* = 6.9 Hz, CHMe), 0.12 (3H, s, MeSi), 0.08 (3H, s, MeSi); ¹³C NMR δ (CDCl₃, 100.6 MHz) 167.9, 149.6, 137.9, 134.0, 130.4, 123.7, 115.3, 92.6, 83.9, 80.2, 76.7, 75.7, 74.4, 72.5, 69.1, 67.4, 63.9, 61.5, 61.0, 59.2, 56.5, 56.1, 51.4, 41.2, 40.8, 40.4, 39.7, 38.7, 37.3, 36.3, 34.8, 34.8, 33.8, 32.4, 32.3, 31.4, 31.2, 28.6, 27.6, 27.5, 25.9, 22.2 (2C), 21.7, 18.0, 17.6, 15.4, 14.2, 12.4, 12.0, 9.4, 8.4, –4.4, –4.8; *m/z* (+ve FAB, NOBA) 1234 (10, [M + Na]⁺), 313 (40), 283 (100), 227 (80); HRMS (+ve FAB, NOBA) [M + Na]⁺ found 1233.8848, C₆₇H₁₃₀O₁₂Si₃Na requires 1233.8768.

Triol Ester (17) To a cooled (0 °C) solution of alcohol **10** (56 mg, 0.0472 mmol) in THF (3 ml) was added HF•py solution (1.0 ml of a stock solution of 2.1 g pyridinium hydrofluoride in 5.7 ml pyridine + 10 ml THF). The reaction mixture was stirred at room temperature for 1 h by which time TLC indicated complete

consumption of starting material. The reaction was quenched with NaHCO₃ (5 ml, sat. aq.) and diluted with EtOAc (10 ml). The layers were separated and the aqueous layer was extracted with EtOAc (3 x 20 ml). The combined organic extracts were washed with CuSO₄ (30 ml, sat. aq), dried (MgSO₄) and concentrated *in vacuo*. Flash column chromatography (30 → 50% EtOAc/hexane) gave **17** as a colourless oil (46 mg, 91%); R_f 0.52 (60% EtOAc/hexane); [α]_D²⁰ -23.8 (*c* 2.0, CHCl₃); IR (liquid film) 3814, 2937, 2865, 1720, 1622, 1462, 1258, 1092, 983 cm⁻¹; ¹H NMR δ (CDCl₃, 500 MHz) 7.34 (1H, d, *J* = 15.7 Hz, 3-CH), 6.04 (1H, br t, *J* = 7.0 Hz, 5-CH), 5.82-5.77 (1H, m, 11-CH), 5.80 (1H, d, *J* = 15.7 Hz, 2-CH), 5.64 (1H, dm, *J* = 10.5 Hz, 10-CH), 4.35-4.33 (1H, m, 9-CH), 4.33-4.27 (1H, br, OH), 4.18-4.13 (1H, m, 7-CH), 4.05 (1H, d, *J* = 10.5 Hz, OH), 3.80-3.75 (2H, m, 32-CH_ACH_B, CHO), 3.75 (3H, s, CO₂Me), 3.71-3.64 (2H, m, 32-CH_ACH_B, 15-CH), 3.58-3.55 (1H, m, CHO), 3.54-3.48 (1H, m, 13-CH), 3.40-3.35 (2H, m, 2xCHO), 3.49 (3H, s, OMe), 3.39 (3H, s, OMe), 3.35 (3H, s, OMe), 3.34 (3H, s, OMe), 3.23-3.18 (1H, m, CHO), 2.97 (1H, dd, *J* = 8.3, 2.8 Hz, CHO), 2.44-2.39 (2H, m, 6-CH₂), 2.08-2.02 (1H, m, CH), 2.02-1.92 (3H, m, 12-CH₂, 30-CH), 1.76 (3H, s, 4-CMe), 1.88-1.70 (6H, m, 14-CH₂, 31-CH_AH_B, 3xCH), 1.68-1.62 (4H, m, 8-CH_AH_B, 16-CH, 2xCH), 1.55-1.50 (2H, m, 2xCH), 1.44-1.38 (2H, m, 8-CH_AH_B, CH), 1.37-1.28 (2H, m, 31-CH_AH_B, CH), 1.06 (18H, br s, (Me₂CH)₃Si), 1.10-1.04 (3H, m, (Me₂CH)₃Si), 1.04 (3H, d, *J* = 7.1 Hz, CHMe), 1.02 (3H, d, *J* = 6.0 Hz, CHMe), 0.92 (3H, d, *J* = 7.1 Hz, CHMe), 0.89 (12H, s+hidden d, SiMe₂Bu, CHMe), 0.86 (3H, d, *J* = 7.2 Hz, CHMe), 0.74 (3H, d, *J* = 7.0 Hz, CHMe), 0.13 (3H, s, MeSi), 0.09 (3H, s, MeSi); ¹³C NMR δ (CDCl₃, 100.6 MHz) 168.0, 149.6, 138.2, 133.9, 130.4, 123.8, 115.2, 92.8, 82.0, 80.8, 80.7, 80.2, 74.3, 72.6, 69.2, 69.1, 67.6, 64.0, 61.4, 61.0, 57.1 (2C), 51.4, 41.3, 40.5, 40.3, 37.5, 36.8, 36.4, 35.6, 34.6, 33.8, 32.9, 32.3, 31.3, 30.9, 30.7, 28.0, 25.9, 18.0, 17.6, 16.5, 14.2, 12.5, 12.1, 12.0, 10.7, 9.2, -4.3, -4.7; *m/z* (+ve FAB, NOBA) 1094 (100, [M+Na]⁺), 1072 (20, [M+H]⁺), 1063 (11), 1038 (7); HRMS (+ve FAB, NOBA) [M+Na]⁺ found 1093.5497, C₅₉H₁₁₄O₁₂Si₂Na requires 1093.7747.

Triol Acid (15) To a solution of ester **17** (96 mg, 0.897 mmol) in MeOH (5 ml) was added dry Ba(OH)₂ (1.0 g, 5.84 mmol). The reaction mixture was stirred at room temperature overnight by which time TLC indicated complete consumption of starting material. The reaction mixture was poured into NH₄Cl (50 ml, sat. aq.) and the aqueous layer acidified to pH 1 with 1 M HCl. The layers were separated and the aqueous extracted with EtOAc (4 x 50 ml). The combined organic extracts were dried (MgSO₄) and concentrated *in vacuo*. Flash column chromatography (5% MeOH/1% AcOH/CH₂Cl₂) gave **15** as a colourless oil (95 mg, 100%); R_f 0.20 (5% MeOH/1% AcOH/CH₂Cl₂); [α]_D²⁰ -24.4 (*c* 1.8, CHCl₃); IR (liquid film) 3420, 2938, 1693, 1622, 1462, 1382, 1265, 1901, 983 cm⁻¹; ¹H NMR δ (CDCl₃, 500 MHz) 7.38 (1H, d, *J* = 15.7 Hz, 3-CH), 6.06 (1H, br t, *J* = 7.3 Hz, 5-CH), 5.78 (1H, d, *J* = 15.7 Hz, 2-CH), 5.80-5.77 (1H, hidden m, 11-CH), 5.64 (1H, dm, *J* = 9.9 Hz, 10-CH), 4.39 (1H, d, *J* = 9.9 Hz, 9-CH), 4.15-4.08 (2H, br m, 7-CH, OH), 3.82 (1H, d, *J* = 10.3 Hz, OH), 3.80-3.75 (2H, m, 32-CH_AH_B, CHO), 3.71-3.66 (1H, m, CHO), 3.58-3.50 (1H, m, CHO), 3.49 (3H, s, OMe), 3.45-3.35 (2H, hidden m, 2xCHO), 3.40 (3H, s, OMe), 3.38 (3H, s, OMe), 3.35 (3H, s, OMe), 3.33-3.30 (1H, m, CHO), 3.28-3.27 (1H, m, CHO), 3.18-3.16 (1H, m, CHO), 2.99 (1H, dd, *J* = 8.5, 2.5 Hz, CHO), 2.50-2.43 (1H, m, 6-CH_AH_B), 2.40-2.32 (1H, m, 6-CH_AH_B), 2.10-1.95 (3H, m, 3xCH), 1.88-1.75 (7H, m, 7xCH), 1.76 (3H, s, 4-CMe), 1.70-1.53 (5H, m, 5xCH), 1.35-1.25 (5H, m, 5xCH), 1.06 (18H, br s, (Me₂CH)₃Si), 1.05-1.04 (3H, m, (Me₂CH)₃Si), 1.03 (3H, d, *J* = 7.1 Hz, CHMe), 1.00 (3H, d, *J* = 6.9 Hz, CHMe), 0.89 (9H, s, SiMe₂Bu), 0.86 (3H, d, *J* = 6.5 Hz, CHMe), 0.84 (3H, d, *J* = 6.5 Hz, CHMe), 0.83 (3H, d, *J* = 6.9 Hz, CHMe), 0.79 (3H, d, *J* = 7.0 Hz, CHMe), 0.14 (3H, s, MeSi), 0.10 (3H, s, MeSi); ¹³C NMR δ (CDCl₃, 100.6 MHz) 170.5, 150.9, 138.8, 134.0, 130.4, 123.8, 115.3, 92.6, 82.2, 80.4, 80.2, 74.0, 72.1, 69.0 (2C), 67.8, 63.7, 61.4, 60.9, 57.4, 57.2, 56.9, 41.1, 41.0, 40.6, 38.3, 36.6, 36.0, 35.7, 34.9, 33.8, 32.1, 31.5 (2C), 30.5, 29.7, 27.1, 25.9, 18.0, 17.5, 16.8, 13.9, 12.4, 11.9, 12.0, 10.4, 9.2, -4.2, -4.7; *m/z* (+ve FAB, NOBA) 1080 (60, [M+Na]⁺), 269 (40), 165 (30), 145 (63), 115 (100); HRMS (+ve FAB, NOBA) [M+Na]⁺ found 1079.5523, C₅₈H₁₁₂O₁₂Si₂Na requires 1079.7590.

Macrolides (16) and (18) To a solution of acid **15** (10.5 mg, 9.9 μmol) in toluene (2 ml) was added Et_3N (7 μl , 50 μmol), 2,4,6-trichlorobenzoylchloride (110 μl , 0.1 M solution in toluene, 11 μmol) and 4-DMAP (20 μl , 0.1 M solution in toluene, 2 μmol). The resulting cloudy solution was stirred at room temperature for 18 h then poured into NaHCO_3 (10 ml, sat. aq.). The aqueous layer was extracted with EtOAc (4 x 10 ml). The combined organic extracts were dried (MgSO_4) and concentrated *in vacuo*. Flash column chromatography (30% EtOAc/hexane) gave a mixture of **16** and **18** (42 : 58 ratio) (9.3 mg, 90%), which were separated by normal phase HPLC (40% EtOAc/hexane).

C₂₁ macrocycle 16: R_f 0.23 (30% EtOAc/hexane); t_R 19 min (40% EtOAc/hexane); $[\alpha]_D^{20}$ -12.7 (*c* 0.45, CHCl_3); IR (liquid film) 3497, 2924, 1689, 1462, 1377, 1264, 1092 cm^{-1} ; $^1\text{H NMR } \delta$ (CDCl_3 , 500 MHz) 7.52 (1H, d, $J = 15.8$ Hz, 3-CH), 5.95 (1H, t, $J = 7.6$ Hz, 5-CH), 5.81-5.78 (1H, m, 11-CH), 5.76 (1H, d, $J = 15.8$ Hz, 2-CH), 5.63 (1H, dm, $J = 10.1$ Hz, 10-CH), 5.17 (1H, d, $J = 10.1$ Hz, 21-CH), 4.43 (1H, d, $J = 10.1$ Hz, 9-CH), 4.13 (1H, d, $J = 4.6$ Hz, OH), 4.16-4.01 (1H, m, 7-CH), 3.80-3.75 (1H, m, 32-CH_AH_B), 3.70-3.65 (2H, m, 32-CH_AH_B, CHO), 3.63-3.58 (1H, m, CHO), 3.52-3.48 (1H, m, 19-CH), 3.48 (3H, s, OMe), 3.40-3.35 (1H, m, 17-CH), 3.36 (3H, s, OMe), 3.25 (3H, s, OMe), 3.20 (3H, s, OMe), 3.21-3.17 (1H, m, CHO), 3.07-3.03 (1H, m, CHO), 2.97 (1H, dd, $J = 8.2, 2.7$ Hz, 23-CH), 2.47-2.44 (2H, m, 6-CH₂), 2.00-1.92 (3H, m, 26-CH_AH_B, 14-CH_AH_B, CH), 1.90-1.70 (7H, m, 12-CH₂, 24-CH, 26-CH_AH_B, 31-CH_AH_B, 18-CH₂), 1.70-1.60 (4H, m, 14-CH_AH_B, 8-CH_AH_B, 2xCH), 1.79 (3H, s, 4-CMe), 1.55-1.50 (2H, m, 16-CH, CH), 1.35-1.22 (4H, m, 31-CH_AH_B, 8-CH_ACH_B, 2xCH), 1.06 (18H, s, (Me₂CH)₃Si), 1.10-1.04 (3H, m, (Me₂CH)₃Si), 1.04 (3H, d, $J = 6.8$ Hz, CHMe), 1.02 (3H, d, $J = 6.7$ Hz, CHMe), 0.89 (9H, s, SiMe₂'Bu), 0.95-0.85 (6H, m, 2xCHMe), 0.83 (3H, d, $J = 6.7$ Hz, CHMe), 0.82 (3H, d, $J = 7.0$ Hz, CHMe), 0.11 (3H, s, MeSi), 0.10 (3H, s, MeSi); $^{13}\text{C NMR } \delta$ (CDCl_3 , 100.6 MHz) 169.3, 150.6, 138.2, 134.4, 130.5, 124.1, 115.6, 92.9, 79.0, 77.2, 76.5, 76.4, 75.9, 73.9, 69.2, 69.1, 64.8, 61.5, 60.9, 58.8, 56.6, 53.8, 41.1, 40.9, 40.8, 40.2, 38.8, 38.0, 37.5, 33.9, 33.7, 32.8, 32.3, 31.8, 31.5, 26.9, 25.8, 23.1, 19.1, 18.0, 17.5, 14.4, 12.2, 11.9, 9.1, 8.9, 8.7, -4.4, -4.8; *m/z* (+ve FAB, NOBA) 1062 (40, [M+Na]⁺), 1040 (80, [M+H]⁺), 510 (50), 497 (50), 428 (60), 399 (60), 269 (100); HRMS (+ve FAB, NOBA) [M+Na]⁺ found 1061.7545, C₅₈H₁₁₀O₁₁Si₂Na requires 1061.7484.

C₂₃ macrocycle 18: R_f 0.30 (30% EtOAc/hexane); t_R 16 min (40% EtOAc/hexane); $[\alpha]_D^{20}$ -3.0 (*c* 0.44, CHCl_3); IR (liquid film) 3503, 2925, 1709, 1462, 1378, 1248, 1086, 978 cm^{-1} ; $^1\text{H NMR } \delta$ (CDCl_3 , 500 MHz) 7.08 (1H, d, $J = 15.8$ Hz, 3-CH), 5.85 (1H, d, $J = 15.8$ Hz, 2-CH), 5.81-5.78 (1H, m, 11-CH), 5.74 (1H, br t, $J = 6.1$ Hz, 5-CH), 5.67 (1H, dm, $J = 10.2$ Hz, 10-CH), 5.00 (1H, dd, $J = 9.8, 1.9$ Hz, 23-CH), 4.47 (1H, d, $J = 10.2$ Hz, 9-CH), 4.08-4.04 (1H, m, 7-CH), 3.96 (1H, d, $J = 9.0$ Hz, OH), 3.88 (1H, d, $J = 9.4$ Hz, OH), 3.80-3.75 (1H, m, 32-CH_AH_B), 3.70-3.60 (3H, m, 32-CH_AH_B, 2xCHO), 3.48-3.42 (1H, m, 19-CH), 3.49 (3H, s, OMe), 3.40 (3H, s, OMe), 3.40-3.32 (1H, m, 17-CH), 3.32 (3H, OMe), 3.25-3.23 (1H, m, CHO), 3.22 (3H, s, OMe), 3.05-3.01 (1H, m, CHO), 2.97 (1H, dd, $J = 8.3, 2.6$ Hz, CHO), 2.54 (1H, dm, $J = 12.3$ Hz, 6-CH_AH_B), 2.32-2.26 (1H, m, 6-CH_AH_B), 2.17-2.10 (1H, m, CH), 2.00-1.90 (2H, m, 18-CH_AH_B, CH), 1.90-1.70 (7H, m, 31-CH_AH_B, 12-CH₂, 8-CH_AH_B, 18-CH_AH_B, 2xCH), 1.70-1.60 (4H, m, 4xCH), 1.77 (3H, s, 4-CMe), 1.55-1.45 (2H, m, 8-CH_AH_B, CH), 1.35-1.20 (4H, m, 4xCH), 1.05 (18H, s, (Me₂CH)₃Si), 1.10-1.04 (3H, m, (Me₂CH)₃Si), 1.03 (3H, d, $J = 7.2$ Hz, CHMe), 1.06-1.03 (3H, hidden d, CHMe), 0.89 (9H, s, SiMe₂'Bu), 0.93 (3H, d, $J = 6.8$ Hz, CHMe), 0.92-0.90 (3H, hidden d, CHMe), 0.82 (3H, d, $J = 7.1$ Hz, CHMe), 0.80 (3H, d, $J = 7.2$ Hz, CHMe), 0.15 (3H, s, MeSi), 0.14 (3H, s, MeSi); $^{13}\text{C NMR } \delta$ (CDCl_3 , 100.6 MHz) 167.5, 146.1, 135.3, 133.9, 130.8, 123.9, 118.0, 93.3, 86.5, 80.1, 79.0, 75.7, 74.3, 70.5, 69.4, 67.8, 64.0, 61.4, 61.1, 57.4, 56.9, 55.8, 42.1, 41.4, 40.7, 39.8, 35.9 (2C), 35.2, 35.0, 33.9, 32.3, 31.9, 31.7, 29.7, 26.0, 25.4, 21.1, 18.0, 17.6, 17.2, 14.6, 14.0, 12.7, 12.0, 9.8, 8.9, -4.4, -4.7; *m/z* (+ve FAB, NOBA) 1062 (80, [M+Na]⁺), 1039 (40, [M+H]⁺), 269 (100); HRMS (+ve FAB, NOBA) [M+Na]⁺ found: 1061.7463, C₅₈H₁₁₀O₁₁Si₂Na requires 1061.7484.

Isomerisation of 18 to 16 To a solution of the C₂₃ macrocycle **18** (10.9 mg, 0.0105 mmol) in CH_2Cl_2 (1 ml) was added $\text{Ti}(\text{O}^i\text{Pr})_4$ (1.0 ml, 1.0 M solution in CH_2Cl_2 , 1.0 mmol). The reaction mixture was stirred at room

temperature for 72 h then poured into HCl (5 ml, 1 M). The layers were separated and the organic layer was washed with NaHCO₃ (5 ml, sat. aq.). The aqueous layers were back extracted with EtOAc (3 x 5 ml) and the combined organic extracts dried (MgSO₄) and concentrated *in vacuo*. Flash column chromatography (30% EtOAc/hexane) gave a mixture containing **16** and **18** in a 2.3 : 1 ratio (46 mg, 91%) which was submitted to HPLC purification as described above.

Reoxidised Macrocycle (6) To a solution of the alcohol **16** (18.4 mg, 0.0177 mmol) in CH₂Cl₂ (4 ml) was added a spatula load of dried 4 Å powdered molecular sieves, followed by NMO (0.249 ml, 0.5 M solution in CH₂Cl₂, 0.125 mmol) and TPAP (0.52 ml, 0.1 M solution in CH₂Cl₂, 5.2 mmol). The reaction mixture was stirred at room temperature for 2 h then loaded directly onto a flash chromatography column (eluting with 10 → 30% EtOAc/hexane), which gave **6** as a colourless oil (14.7 mg, 80%); R_f 0.55 (30% EtOAc/hexane); [α]_D²⁰ -4.7 (*c* 0.45, CHCl₃); IR (liquid film) 2923, 1693, 1691, 1461, 1376, 1264, 1092 cm⁻¹; ¹H NMR δ (CDCl₃, 500 MHz) 7.52 (1H, d, *J* = 15.3 Hz, 3-CH), 5.96 (1H, t, *J* = 7.6 Hz, 5-CH), 5.81-5.77 (1H, m, 11-CH), 5.76 (1H, d, *J* = 15.3 Hz, 2-CH), 5.63 (1H, dm, *J* = 10.0 Hz, 10-CH), 5.16 (1H, d, *J* = 9.9 Hz, 21-CH), 4.43 (1H, br d, *J* = 10.0 Hz, 9-CH), 4.19 (1H, d, *J* = 4.6 Hz, 23-OH), 4.04-4.02 (1H, m, 7-CH), 3.79-3.76 (1H, m, 32-CH_AH_B), 3.68 (1H, td, *J* = 9.0, 5.6 Hz, 32-CH_AH_B), 3.62 (1H, d, *J* = 8.6 Hz, CHO), 3.53 (1H, br t, *J* = 5.6 Hz, CHO), 3.54-3.45 (1H, m, CHO), 3.40-3.33 (1H, m, CHO), 3.37 (3H, s, OMe), 3.30 (3H, s, OMe), 3.33-3.28 (1H, m, 29-CH), 3.25 (3H, s, OMe), 3.21 (3H, s, OMe), 3.06-3.02 (1H, m, 23-CH), 2.85-2.82 (1H, m, 28-CH), 2.63 (1H, ddd, *J* = 17.9, 8.5, 5.1 Hz, 26-CH_AH_B), 2.51-2.43 (3H, m, 26-CH_AH_B, 6-CH₂), 2.20-1.85 (4H, m, 20-CH, 22-CH, 24-CH, CH), 1.79 (3H, s, 4-CMe), 1.85-1.65 (7H, m, 12-CH₂, 25-CH_AH_B, 31-CH_AH_B, 8-CH_AH_B, 2xCH), 1.50-1.20 (6H, m, 25-CH_AH_B, 31-CH_AH_B, 8-CH_AH_B, 3xCH), 1.06 (18H, s, (Me₂CH)₃Si), 1.10-1.04 (3H, m, (Me₂CH)₃Si), 1.01 (6H, br d, *J* = 7.0 Hz, 2xCHMe), 0.95 (3H, d, *J* = 7.0 Hz, CHMe), 0.89 (12H, s + hidden d, SiMe₂Bu + CHMe), 0.84 (3H, d, *J* = 6.8 Hz, CHMe), 0.83 (3H, d, *J* = 7.0 Hz, CHMe), 0.12 (3H, s, MeSi), 0.11 (3H, s, MeSi); ¹³C NMR δ (CDCl₃, 100.6 MHz) 214.9, 169.3, 150.7, 138.3, 134.4, 130.5, 124.0, 115.5, 88.4, 79.0, 77.2, 76.5, 76.4, 75.7, 69.5, 69.1, 64.8, 61.3, 60.8, 58.8, 56.7, 53.8, 48.4, 41.7, 41.1, 40.8, 40.2, 38.8, 38.0, 37.5, 33.3, 33.0, 32.9, 31.8, 30.9, 29.7, 25.8, 21.8, 18.0, 17.8, 17.1, 13.6, 12.2, 12.0, 9.0, 8.8, 8.7, -4.4, -4.8; *m/z* (+ve FAB, NOBA) 1059 (30, [M+Na]⁺), 1020 (90), 419 (60), 307 (90), 269 (100); HRMS (+ve FAB, NOBA) [M+Na]⁺ found 1059.7321, C₅₈H₁₀₈O₁₁Si₂Na requires 1059.7328.

Deprotected Macrocycle (7) To a solution of macrocycle **6** (38.6 mg, 0.0134 mmol) in THF (2 ml) was added HF•py solution (4.0 ml of a stock solution of 2.1 g pyridinium hydrofluoride in 5.7 ml pyridine + 10 ml THF). The reaction mixture was stirred at room temperature for 24 h before a further aliquot of HF•py (3 ml) was added. After stirring at room temperature for 24 h, the reaction mixture was cooled to 0 °C, quenched with NaHCO₃ (10 ml, sat. aq.) and extracted with EtOAc (10 ml). The layers were separated and the aqueous layer was extracted with EtOAc (4 x 20 ml). The combined organic extracts were dried (MgSO₄) and concentrated *in vacuo*. Preparative TLC (EtOAc) gave **7** as a colourless oil (18.2 mg, 64%), as well as a mixture of monodeprotected products (12.2 mg, ~36%); R_f 0.24 (EtOAc); [α]_D²⁰ -23.0 (*c* 0.29, CHCl₃); IR (liquid film) 3444, 2934, 1680, 1458, 1376 1266, 1087 cm⁻¹; ¹H NMR δ (CDCl₃, 500 MHz) 7.53 (1H, d, *J* = 15.8 Hz, 3-CH), 5.95 (1H, t, *J* = 9.1 Hz, 5-CH), 5.84-5.81 (1H, m, 11-CH), 5.77 (1H, d, *J* = 15.8 Hz, 2-CH), 5.65 (1H, dm, *J* = 10.1 Hz, 10-CH), 5.18 (1H, d, *J* = 10.2 Hz, 21-CH), 4.55 (1H, dm, *J* = 10.1 Hz, 9-CH), 4.14 (1H, d, *J* = 4.7 Hz, 23-OH), 4.10-4.05 (1H, m, 7-CH), 3.77-3.72 (1H, m, 32-CH_AH_B), 3.60 (1H, dm, *J* = 8.4 Hz, 15-CH), 3.60-3.56 (1H, m, 32-CH_AH_B), 3.46-3.42 (1H, m, 19-CH), 3.36-3.32 (2H, hidden m, 17-CH, 29-CH), 3.36 (3H, s, OMe), 3.35 (3H, s, OMe), 3.22-3.19 (1H, hidden m, 13-CH), 3.22 (6H, s, 2xOMe), 3.05-3.01 (1H, m, 23-CH), 2.96-2.90 (1H, m, 28-CH), 2.63-2.60 (1H, m, 26-CH_AH_B), 2.58-2.45 (3H, m, 26-CH_AH_B, 6-CH₂), 2.05-1.85 (5H, m, 22-CH, 20-CH, 30-CH, 12-CH₂), 1.79 (3H, s, 4-CMe), 1.80-1.73 (4H, m, 25-CH_AH_B, 18CH₂, 8-CH_AH_B), 1.70-1.60 (6H, m, 16-CH, 31-CH₂, 24-CH, 14-CH₂),

1.40–1.45 (1H, m, 25-CH_AH_B), 1.25–1.30 (1H, m, 8-CH_AH_B), 1.04 (3H, d, $J = 7.0$ Hz, 30-CHMe), 1.01 (3H, d, $J = 6.8$ Hz, 24-CHMe), 0.95 (3H, d, $J = 7.0$ Hz, 28-CHMe), 0.92 (3H, d, $J = 7.0$ Hz, 20-CHMe), 0.83 (3H, d, $J = 6.8$ Hz, 16-CHMe), 0.82 (3H, d, $J = 6.9$ Hz, 22-CHMe); ¹³C NMR δ (CDCl₃, 100.6 MHz) 214.5, 169.3, 150.4, 137.5, 134.7, 130.1, 124.5, 115.7, 87.7, 78.7, 76.7, 76.5, 75.8, 70.0, 66.7, 65.8, 65.4, 61.1, 59.3, 58.6, 56.8, 53.4, 48.4, 41.7, 40.5, 40.3, 38.5, 37.8, 37.4, 33.0 (2C), 32.5, 32.0, 31.8, 21.8, 17.8, 16.8, 15.3, 13.6, 12.2, 9.0, 8.9, 8.6; m/z (+ve FAB, NOBA) 789 (10, [M+Na]⁺), 750 (80), 718 (30), 391 (60), 307 (100); HRMS (+ve FAB, NOBA) [M+Na]⁺ found 789.5132, C₄₃H₇₄O₁₁Na requires 789.5129.

C₃₂ Aldehyde (8) To a cooled (0 °C) solution of **7** (15.5 mg, 20.3 μ mol) was added a spatula load of dried 4 Å powdered molecular sieves followed by NMO (1.4 ml, 0.1 M solution in CH₂Cl₂, 102 μ mol) and TPAP (81 μ l, 0.05 M solution in CH₂Cl₂, 4.1 μ mol). The green solution was stirred at this temperature for 30 min then loaded directly onto a flash chromatography column which was eluted with EtOAc. Preparative TLC (EtOAc) gave **8** (10.1 mg, 65%) as a colourless oil; R_f 0.70 (EtOAc); $[\alpha]_D^{20} -13.6$ (c 0.22, CHCl₃); IR (liquid film) 3418, 2973, 1679, 1650, 1266, 1087 cm⁻¹; ¹H NMR δ (CDCl₃, 500 MHz) 9.75 (1H, br s, CHO), 7.54 (1H, d, $J = 15.8$ Hz, 3-CH), 5.97–5.92 (1H, m, 5-CH), 5.84–5.81 (1H, m, 11-CH), 5.77 (1H, d, $J = 15.8$ Hz, 2-CH), 5.66 (1H, dm, $J = 10.2$ Hz, 10-CH), 5.18 (1H, d, $J = 9.9$ Hz, 21-CH), 4.55 (1H, dm, $J = 10.2$ Hz, 9-CH), 4.16 (1H, d, $J = 4.4$ Hz, 23-OH), 4.10–4.07 (1H, m, 7-CH), 3.61 (1H, d, $J = 8.4$ Hz, 15-CH), 3.48–3.45 (1H, m, 19-CH), 3.36 (3H, s, OMe), 3.30 (3H, s, OMe), 3.35–3.20 (3H, hidden m, 29-CH, 17-CH, 13-CH), 3.22 (3H, s, OMe), 3.21 (3H, s, OMe), 3.05–3.02 (1H, m, 23-CH), 2.76–2.70 (1H, m, 28-CH), 2.63 (1H, ddd, $J = 17.6, 8.3, 5.2$ Hz, 26-CH_ACH_B), 2.60–2.50 (2H, m, 6-CH₂), 2.52–2.45 (2H, m, 26-CH_ACH_B, 31-CH_ACH_B), 2.30–2.26 (2H, m, 31-CH_ACH_B, 30-CH), 2.05–1.85 (4H, m, 22-CH, 20-CH, 12-CH₂), 1.80 (3H, s, 4-CMe), 1.80–1.60 (8H, m, 25-CH_ACH_B, 8-CH_ACH_B, 18-CH₂, 16-CH, 24-CH, 14-CH₂), 1.48–1.40 (1H, m, 25-CH_ACH_B), 1.27–1.22 (1H, m, 8-CH_ACH_B), 1.04 (6H, d, $J = 7.1$ Hz, 30-CHMe, 28-CHMe), 1.01 (3H, d, $J = 6.4$ Hz, 24-CHMe), 0.91 (3H, d, $J = 7.0$ Hz, 20-CHMe), 0.83 (3H, d, $J = 6.7$ Hz, 22-CHMe), 0.82 (3H, d, $J = 6.9$ Hz, 16-CHMe); ¹³C NMR δ (CDCl₃, 100.6 MHz) 213.7, 201.9, 169.3, 150.5, 137.5, 134.7, 130.1, 124.5, 115.7, 87.4, 78.6, 76.7, 76.4, 75.7, 70.0, 68.7, 66.6, 60.6, 60.4, 58.6, 56.8, 48.7, 46.1, 41.1, 40.5, 40.3, 40.2, 38.5, 37.8, 37.4, 32.9, 32.4, 31.8, 30.9, 21.9, 18.2, 17.8, 14.2, 13.2, 12.2, 9.0, 8.8, 8.8; m/z (+ve FAB, NOBA) 788 (100, [M + Na]⁺), 766 (10, [M + H]⁺), 482 (10), 460 (20); HRMS (+ve FAB, NOBA) [M+Na]⁺ found 787.5008, C₄₃H₇₂O₁₁Na requires 787.4972.

Scytophycin C (1) To a solution of aldehyde **8** (5.0 mg, 6.5 mmol) in *N*-methylformamide (1 ml) was added P₂O₅ (~4 mg) and the resulting yellow solution was stirred at room temperature for 30 min. The reaction mixture was quenched with NaHCO₃ (5 ml, sat. aq.) and the aqueous layer extracted with EtOAc (4 x 10 ml). The combined organic extracts were dried (MgSO₄) and concentrated *in vacuo*. The crude material was loaded onto a short column of reverse phase silica (Mitsubishi Kasei Corporation MCI GEL CHP20P (70–150 μ)), eluting with 50% → 80% → 100% MeOH/H₂O. Further purification by reverse phase HPLC (80% MeOH/H₂O) gave **1** as a colourless oil (1.0 mg, 20%); R_f 0.43 (1:1:1 EtOAc:hexane:acetone); t_R 19 min (80% MeOH/H₂O); IR (liquid film) 3420, 1642, 1110 cm⁻¹; ¹H NMR δ (CD₃COCD₃), 500 MHz) see **Table 1**; ¹³C NMR δ (CD₃COCD₃, 500 MHz, HMQC) see **Table 2**; m/z (+ve FAB, NOBA) 828 (10, [M+Na]⁺), 805 (25, [M+H]⁺), 788 (30, [M - H₂O + H]⁺), 789 (100), 730 (90); HRMS (+ve FAB, NOBA) [M]⁺ found 805.5389, C₄₅H₇₅NO₁₁ requires 805.5340.

Table 1: ^1H NMR Data in CD_3COCD_3 for scytophycin C (**1**)

Assignment	$\delta_{\text{H}}^{\text{a}}$	Mult	J Hz	$\delta_{\text{H}}^{\text{b}}$ (Lit ⁵)	Mult ^c	J Hz
2	5.77	d	15.7	5.78	d	15.8
3	7.61	d	15.8	7.61	d	15.8
Me on 4	1.82	s		1.82	br s	
5	6.04	m		6.03	br d d	9.3, 4.3
6	2.47	m		2.46	m	
7	4.03	br t m		4.02	br t d	10.2, 3.1
8	1.26	m		1.28	ddd	14.7, 10.2, 1.8
8'	1.74	m		1.77	ddd	14.7, 9.8, 1.2
9	4.53	m		4.53	br d	9.8
10	5.68	br d	10.1	5.67	d d t	10.4, 2.9, 1.8
11	5.77	m		5.77	d t d	10.4, 4.0, 1.6
12	1.90	m		1.89	m	
13	3.34	m		3.34	m	
14	1.68	m		1.68	-	
14'	1.63	m		1.63	ddd	14.5, 8.4, 3.1
15	3.63	d m	8.0	3.62	dd	7.4, 3.1
MeO on 15	3.30	s		3.30	s	
16	1.67	m		1.68	-	
Me on 16	0.80	d	7.0	0.80	d	-
17	3.26	d m	11.9	3.26	dd	11.4, 4.0
MeO on 17	3.24	s		3.23	s	
18	1.75	m		1.73	ddd	13.6, 9.7, 4.0
18'	1.85	m		1.83	ddd	13.6, 11.4, 4.0
19	3.48	m		3.47	ddd	9.7, 4.0, 1.0
MeO on 19	3.17	s		3.17	s	
20	2.00	m		2.04	m	
Me on 20	0.91	d	6.8	0.89	d	7.0
21	5.17	d	9.5	5.16	br d	10.3
22	2.00	m		2.00	m	
Me on 22	0.85	d	6.8	0.84	d	6.8
23	3.02	d m	9.7	3.00	dd	9.7, 2.0
24	1.68	m		1.67	m	
Me on 24	0.98	d	6.7	0.97	d	6.7
25	1.36	m		1.38	m	
25'	1.77	m		1.76	m	
26	2.53	m		2.55	m	
28	2.78	m		2.77	dq	9.5, 7.0
Me on 28	0.91	d	6.8	0.90	d	7.0
29	3.27	m		3.27	dd	9.5, 2.2
MeO on 29	3.29	s		3.29	s	
30	2.45	m		2.44	m	
Me on 30	1.14	d	7.0	1.13	d	7.0
31	5.11	dd	14.1, 9.2	5.12	dd	14.1, 9.2
31 ^d	5.17	dd	14.9, 8.5	5.17	dd	14.8, 9.0
32	6.77	d	14.2	6.77	d	14.1
32 ^d	7.10	d	14.6	7.09	d	14.8
Me on N	2.98	s		2.97	s	
Me on N ^d	3.09	s		3.09	s	
NCHO	8.35	s		8.34	s	
NCHO ^d	8.10	s		8.09	s	

^aMeasured at 500 MHz. Assignments were determined by COSY experiment. ^bMeasured at 300 MHz. ^cCoupling constants given for scytophycin B. ^dSignals for minor conformer.

Table 2: ^{13}C NMR Data in CD_3COCD_3 for scytophycin C (**1**)

Assignment	$\delta_{\text{C}}^{\text{a}}$	$\delta_{\text{C}}^{\text{b}}$ (Lit ⁵)
1	-	169.38
2	115.0	115.71
3	-	151.33
4	-	134.69
Me on 4	11.3	12.09
5	138.0	139.73
6	41.4	41.92
7	69.0	68.54
8	40.8	41.19
9	70.2	70.76
10	131.3	131.48
11	124.3	124.48
12	31.2	32.19
13	66.2	65.75
14	32.0	32.61
15	77.2	79.79
MeO on 15	55.8	56.46
16	39.5	40.93
Me on 16	8.0	9.25
17	-	76.32
MeO on 17	53.0	53.55
18	-	27.31
19	77.2	77.93
MeO on 19	57.5	58.03
20	40.0	40.29
Me on 20	8.6	9.05
21	76.0	76.56
22	39.0	38.45
Me on 22	8.2	8.79
23	77.0	77.18
24	33.2	33.69
Me on 24	17.3	18.13
25	-	22.55
26	40.0	39.17
27	-	213.84
28	49.0	49.33
Me on 28	12.7	13.47
29	87.4	88.11
MeO on 29	60.8	60.96
30	-	38.03
30 ^c	38.3	38.18
Me on 30	18.7	19.45
31	111.2	110.97
31 ^c	113.0	113.05
32	129.8	129.98
32 ^c	124.9	125.46
Me on N	26.5	27.03
Me on N ^c	32.0	32.85
CHO	-	162.71
CHO ^c	-	161.62

^aValues obtained by HMQC experiment. ^bMeasured at 300 MHz. ^cSignals for minor conformer.

Acknowledgements: We thank the EPSRC (GR/K54052), Zeneca Pharmaceuticals (CASE studentship to CW) and the Croucher Foundation (Scholarship to KSY) for their support, Dr. Roger Butlin (Zeneca) for helpful discussions and Ray Finlay (Cambridge) for NMR assistance.

References and Notes

1. Paterson, I.; Yeung, K.-S.; Watson, C.; Ward, R. A.; Wallace, P. A. *Tetrahedron* **1998**, *54*, 11935.
2. For a preliminary account of some of this work, see: Paterson, I.; Watson, C.; Yeung, K.-S.; Wallace, P. A.; Ward, R. A. *J. Org. Chem.* **1997**, *62*, 452.
3. (a) Paterson, I.; Smith, J. D.; Ward, R. A.; Cumming, J. G. *J. Am. Chem. Soc.* **1994**, *116*, 2615. (b) Paterson, I.; Yeung, K.-S.; Ward, R. A.; Smith, J. D.; Cumming, J. G., Lambole, S. *Tetrahedron*, **1995**, *51*, 9467.
4. Inanaga, J.; Hirata, K.; Saeki, H.; Katsuki, T.; Yamaguchi, M. *Bull. Chem. Soc. Jpn.* **1979**, *52*, 1989.
5. Ishibashi, M.; Moore, R. E.; Patterson, G. M. L.; Xu, C.; Clardy, J. *J. Org. Chem.*, **1986**, *51*, 5300.
6. McMurray, J. *Org. React.* **1976**, *24*, 187.
7. (a) Laganis, E. D.; Chenard, B. L. *Tetrahedron Lett.* **1984**, *25*, 5831. (b) Bhagwat, S. S.; Hamann, P. R.; Still, W. C. *J. Am. Chem. Soc.* **1985**, *107*, 6372.
8. (a) Dess, D. B.; Martin, J. C. *J. Org. Chem.* **1983**, *48*, 4155. (b) Dess, D. B.; Martin, J. C. *J. Am. Chem. Soc.* **1991**, *113*, 7277. (c) Ireland, R. E.; Liu, L. *J. Org. Chem.* **1993**, *58*, 2899. (d) Meyer, S. D.; Schreiber, S. L. *J. Org. Chem.* **1994**, *59*, 7549.
9. For a selective deprotection in a similar situation, see: Evans, D. A.; Kaldor, S. W.; Jones, T. K.; Clardy, J.; Stout, T. J. *J. Am. Chem. Soc.* **1990**, *112*, 7001.
10. Hikota, M.; Sakurai, Y.; Horita, K.; Yonemitsu, O. *Tetrahedron Lett.* **1990**, *31*, 6367.
11. Boden, E. P.; Keck, G. E. *J. Org. Chem.* **1985**, *50*, 2394.
12. Mukaiyama, T.; Usui, M.; Saigo, K. *Chem. Lett.* **1976**, 49.
13. (a) For a review of transesterification reactions, see: Otera, J. *Chem. Rev.* **1993**, *93*, 1449. (b) Seebach, D.; Hungerbühler, E.; Naef, R.; Schnurrenberger, P.; Weidmann, B.; Züger, M. *Synthesis* **1982**, 138.
14. (a) Kigoshi, H.; Suenaga, K.; Mutou, T.; Ishigaki, T.; Atsumi, T.; Ishiwata, H.; Sakakura, A.; Ogawa, T.; Ojika, M.; Yamada, K. *J. Org. Chem.* **1996**, *61*, 5326. (b) Ojika, M.; Kigoshi, H.; Ishigaki, T.; Tsukada, I.; Tsuboi, T.; Ogawa, T.; Yamada, K. *J. Am. Chem. Soc.* **1994**, *116*, 7441. (c) Kigoshi, H.; Ojika, M.; Ishigaki, T.; Suenaga, K.; Mutou, T.; Sakakura, A.; Ogawa, T.; Yamada, K. *J. Am. Chem. Soc.* **1994**, *116*, 7443.
15. Otera, J.; Dan-oh, N.; Nozaki, H. *J. Org. Chem.* **1991**, *56*, 5307.
16. Ley, S. V.; Norman, J.; Griffith, W. P.; Marsden, S. P. *Synthesis* **1994**, *7*, 639.
17. Paterson, I.; Cowden, C.; Watson, C. *Synlett* **1996**, 209.
18. Unfortunately, an authentic sample of scytophycin C was not available from the Hawaii group (Dr G. M. L. Patterson) for direct comparison.